Member Info for JoeyDiamond

Denmark have announced they will no longer offer mRNA vaccines to 18 and under. From risk/benefit analysis is the correct decision. Possibly will see other countries follow suit.

https://mobile.twitter.com/TracyBethHoeg/status/1557039855304990721

Stunning prospective study from Thailand
Of 301 13-18 year olds following dose 2 pfizer.

18% had abnormal EKG post vax

3.5% (7/202) males & 0 females developed myoperi/peri or subclinical myocarditis, 2 were hospitalized w/1 being observed in the ICU

https://preprints.org/manuscript/202208.0151/v1

Dexamethasone is a dual edged sword, it reduces inflammation but at a cost of dampening the bodies immune/anti viral response.

Remember India and all those secondary fungal infection stories, people taking Dexamethasone too early in disease course was a contributing factor. In India people could get hold of the drug prior to being hospitalised during the viral load stage. By dampening the immune response it made people very susceptible to secondary infections like Mucormycosis.

In UK hospitals its common for secondary infections like Staph to take hold in Covid patients. Why when giving Dex they would also give a course of antibiotics knowing they would be opening the door to infections with bodies immune response dampened.

Timing of Dexamethasone is crucial.

Mad that the peer review of these findings has taken a full year to complete. This research was shared here in July 2021 as a preprint.

Peer review of Sprinter may be a long time off :)

Its also a wonderful thing that the AAB and inborn error science preprints back in 2020 were first discovered and discussed on this very message board. We then shared the info with the company so us internet sleuths and amateur scientists may have helped in a little way :)

The autoantibodies science in my opinion is a big reason why we may get a 2nd chance with a platform trial. So for me was a key question to be answered at the AGM, the response from the likes of SSH or RM would be very telling.

Look forward to reading it. Will there be a video or audio recording of the AGM at a later date?

Directors lose the ability to independently decide to raise cash via dilution. Effectively they now need permission first from shareholders (ie Polygons blessing) to do this.

SNG are well funded past June 2023 if nothing changes (Salaries/lease were £3 million/year)

The only reason for a cash raise would be for a material change of situation eg ramping back up commercialisation. But by then SP would be much higher if commercialisation was back on the cards.

I think people are looking at it the wrong way, this is a way of company raising cash quickly for positive reasons

https://www.lsegissuerservices.com/spark/Synairgen/events/1cd87eb6-5e01-4e1a-b3bd-f8288bbb6b5b

Aether 12 and 13 will likely be the same resolutions as last years AGM and prior years. Basically ability to raise cash by issuing more shares.

No broker note expects cash to be fine until 2024, so cash position has actually improved from previous update.

The RNS was as expected reaffirming what we already know. Cash position looks ok so fears of a cash raise subsided for a while.

The people 'alarmed' are just the traders who pumped yesterday on the run up to news and then dumped on the day. Standard AIM procedure.

Phizer have a habit of fabricating data for trials. No wonder they won't release the drug for combination trials.

Doc83 best guess is a platform trial next or I hope some form of joint venture.

I think you are correct the EUA application is taking a long time so suspect after Fluvoxamine review Eiger are rewriting it )

On the subject of Eiger they are planning to submit an EUA b4 30th June

Pretty much only the Brazil trial sites showed efficacy in Molnupirivirs trials.

https://mobile.twitter.com/boulware_dr/status/1526254753075892224

Mercks drug got approval based on the same metrics and trialling in the same country.

FDA are corrupted but that’s to be expected when they are part funded by big pharma. Sadly this is what the little guys are up against.

If around 100 extra patients were dosed in Sprinter they will have likely just scraped a statistical significant result on a secondary endpoint.

This is why Sprinter was so frustrating as trial design/numbers rather than interferon itself was the reason for failure.

Doc83 I don't think they will have passed futility test on the primary endpoints. Only the main secondary endpoints will likely have passed the futility test to keep the trial going.

As per Sprinter protocol, the decision by the futility board is 'yes carry on' providing a secondary endpoint can be achieved even if primary endpoints are doomed.